Ultragenyx制药 RARE 深 沪
等待开盘 11-25 09:30:00 美东时间
32.82
-0.770
-2.29%
华盛通- 最 高34.20
- 今 开33.26
- 成交量 113.44万股
- 最 低 32.705
- 昨 收 33.59
- 总市值 31.66亿
- 52周最高 50.00
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 25.81
- 委 比 -69.37%
- 总股本 9647.76万
- 历史最高 179.647
- 量 比 1.27
- 振 幅 4.45%
- 历史最低 25.81
- 每 手 1
- 风险率 5.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $50
Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $81 to $50.
11-24 22:42
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc.授予了12名新聘非高管员工总计18,180股限制性股票单位，这些股票分四年解锁，每年解锁25%，并需符合纳斯达克上市规则。公司致力于开发罕见及超罕见疾病新型疗法，由经验丰富的管理团队领导，专注于高效药物开发以满足未竟医疗需求。 Ultragenyx Pharmaceutical Inc.授予12位新入职非高管员工18,180股限制性股票单位，股票按四年计划解锁，每年解锁25%，需符合纳斯达克规则。公司专注罕见病治疗，目标是开发高效药物以满足高未竟医疗需求。
11-21 21:30
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative Aimed At Advancing Research For Rare Ocular Disorders
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate
10-30 21:07
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On October 30, 2...
10-30 20:55
What to Expect from Kiniksa Pharmaceuticals's Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly ear...
10-28 03:01
Headwaters Capital falls 2.7% in Q3; adds Driven Brands, exits Bentley Systems
The Headwaters Capital Management, LLC portfolio declined -2.7% during Q3 2025 compared to a +5.3% gain for the Russell Mid Cap Index over the same period. Driven Brands (NASDAQ:DRVN): A new starter p...
10-17 01:05
Tactical Resources Advances Nasdaq Listing Amid Strategic Rare Earth Developments
Tactical Resources Corp. ( ($TSE:RARE) ) has shared an update. Tactical Resourc...
10-17 00:39
ClearBridge SMID Cap Growth Strategy
The ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth Index benchmark during the third quarter, with the index gaining 10.7%. As such, the performance of SMID growth equitie...
10-13 23:15
